Russell Frank Company’s Celldex Therapeutics CLDX Stock Holding History

Russell Frank Company’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$56K	Hold	995	–	–	﹤0.01%	2854
2015 Q4	$241K	Hold	995	–	–	﹤0.01%	2661
2015 Q3	$157K	Sell	995 -498	-33%	-$141K	﹤0.01%	2749
2015 Q2	$564K	Buy	1,493 +995	+200%	+$395K	﹤0.01%	2541
2015 Q1	$208K	Sell	498 -2,597	-84%	-$929K	﹤0.01%	2638
2014 Q4	$844K	Buy	3,095 +2,597	+521%	+$646K	﹤0.01%	2227
2014 Q3	$97K	Sell	498 -932	-65%	-$203K	﹤0.01%	2666
2014 Q2	$282K	Sell	1,430 -794	-36%	-$179K	﹤0.01%	2476
2014 Q1	$487K	Sell	2,224 -11,392	-84%	-$4.36M	﹤0.01%	2395
2013 Q4	$5.3M	Buy	13,616 +2,823	+26%	+$1.09M	0.01%	1199
2013 Q3	$5.74M	Sell	10,793 -4,486	-29%	-$1.54M	0.01%	1245
2013 Q2	$3.58M	Buy	+15,279	New	+$3.01M	0.01%	1440

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Russell Frank Company's CLDX Position: Q1 2016 in Review

Russell Frank Company held its Celldex Therapeutics (CLDX) position steady in Q1 2016 at 995 shares worth $56K. The position accounts for ﹤0.01% of the portfolio, ranked #2854.

Russell Frank Company first reported a position in CLDX in Q2 2013 and has held it in 12 quarters since. The position peaked at $5.74M in Q3 2013. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

Russell Frank Company held 995 shares of Celldex Therapeutics worth $56K as of Q1 2016.
Russell Frank Company left its Celldex Therapeutics share count unchanged in Q1 2016.
Celldex Therapeutics made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2854 holding.
Russell Frank Company first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 12 quarters since.
Russell Frank Company's Celldex Therapeutics position peaked at $5.74M in Q3 2013.
145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.